Company intelligence / Profile preview

Ourotech

Waterloo, Ontario, Canada6sense.com ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Ourotech has developed proprietary hydrogels and microfluidic devices that allow culturing of patient-derived tumor samples outside the body. These platforms mimic the mechanical and biochemical properties of solid tumors—including pH and oxygen gradients—to better predict drug resistance. Clinical studies are underway in triple negative breast cancer, glioma/brain tumors, and kidney cancers to validate the predictive power of their assay for therapy selection. No direct therapeutic results as they are a diagnostics/platform company.

Therapeutic areas: Oncology
Modalities: Hydrogel-based drug screening technology
Industry: Consumable Medical Devices

Partnerships

Merck KGaA Innovation Center program

Beyond the preview

Go deeper on Ourotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ourotech.

Explore the full profile